RECRUITING

Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

Conditions

Chronic Low-back Pain Degenerative Disc Disease

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The brief purpose of this research study is to learn about the safety, tolerability, and efficacy of paraspinal intramuscular injection of CELZ-201-DDT in patients with chronic lower back pain.

Official Title

A Double-blinded, Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Effectiveness of CELZ-201-DDT Administered by Intramuscular Injection for the Treatment of Chronic Lower Back Pain in Patients With Degenerative Disc Disease

Quick Facts

Study Start:2024-05-21

Study Completion:2026-05-21

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06053242

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Ability of participant to understand and the willingness to sign a written informed consent document. * Between 18-80 years of age and may be of either gender or any race. * Subjects must have failed at least two standard of care (SOC) therapies before being enrolled in the study: 1) exercise/physical therapy; 2) oral analgesic including nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; 3) skeletal muscle relaxants. Subjects must have tried each SOC therapy for at least 3 months before failure is determined. * Patients must have failed the SOC therapies within 12 months of enrollment in the clinical trial. * Proof for one of the following tests already performed in the clinical care of the patient for lower back pain: 1) MRI scan demonstrating at least one disc level with grade II or greater disc degeneration using the Pfirrmann grading system; 2) Oswestry Disability Index for Back Pain score of 21-80%; 3) Visual Analogue Scale for pain of \>5 on a scale of 0-10. * Female subjects must not be breast feeding and must have no intention to become pregnant during the study, and she is using contraceptive drugs or devices. * Any male subject must agree to use contraceptives and not donate sperm during the study.	* History of cancer in the last five years. * Spinal infections and spinal tumors. * Renal insufficiency requiring dialysis or an eGFR of less than 60 mL/min/1.73m2. * ALT, AST greater than 2 times or Total Bilirubin 1.5 times the upper limit of the normal range. * Positive pregnancy test. * History of blood cell diseases. * Uncontrolled diabetes mellitus - HgA1c \>8%. * Uncontrolled hypertension defined as a systolic blood pressure of \>140 mmHg or diastolic blood pressure of \>90 mmHg at the time of screening. If subjects have their hypertension appropriately treated, then they would be eligible to enroll. * Patients known to have any active infection, including infection of the injection site(s), and/or any active systemic or local infection. * Patients on chronic immunosuppressive transplant therapy. Patients receiving \<5 mg of Prednisone daily may be included. * Subjects having a concomitant life-threatening disease in which their life expectancy is estimated to be less than 2 years. * Recent smoking history or substance abuse (within six weeks). * Heavy alcohol use (greater than 14 drinks per week for men or 7 drinks per week for women per NIAAA) * Use of an investigational drug, device or product, or participation in a drug research study within a period of 30 days prior to receiving study treatment. * Any patient who has received gene therapy in the past. * Subjects who are currently on opioid medication(s). * Body Mass Index (BMI) \> 40 kg/m2.

Inclusion Criteria

Exclusion Criteria

* Ability of participant to understand and the willingness to sign a written informed consent document.
* Between 18-80 years of age and may be of either gender or any race.
* Subjects must have failed at least two standard of care (SOC) therapies before being enrolled in the study: 1) exercise/physical therapy; 2) oral analgesic including nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; 3) skeletal muscle relaxants. Subjects must have tried each SOC therapy for at least 3 months before failure is determined.
* Patients must have failed the SOC therapies within 12 months of enrollment in the clinical trial.
* Proof for one of the following tests already performed in the clinical care of the patient for lower back pain: 1) MRI scan demonstrating at least one disc level with grade II or greater disc degeneration using the Pfirrmann grading system; 2) Oswestry Disability Index for Back Pain score of 21-80%; 3) Visual Analogue Scale for pain of \>5 on a scale of 0-10.
* Female subjects must not be breast feeding and must have no intention to become pregnant during the study, and she is using contraceptive drugs or devices.
* Any male subject must agree to use contraceptives and not donate sperm during the study.

* History of cancer in the last five years.
* Spinal infections and spinal tumors.
* Renal insufficiency requiring dialysis or an eGFR of less than 60 mL/min/1.73m2.
* ALT, AST greater than 2 times or Total Bilirubin 1.5 times the upper limit of the normal range.
* Positive pregnancy test.
* History of blood cell diseases.
* Uncontrolled diabetes mellitus - HgA1c \>8%.
* Uncontrolled hypertension defined as a systolic blood pressure of \>140 mmHg or diastolic blood pressure of \>90 mmHg at the time of screening. If subjects have their hypertension appropriately treated, then they would be eligible to enroll.
* Patients known to have any active infection, including infection of the injection site(s), and/or any active systemic or local infection.
* Patients on chronic immunosuppressive transplant therapy. Patients receiving \<5 mg of Prednisone daily may be included.
* Subjects having a concomitant life-threatening disease in which their life expectancy is estimated to be less than 2 years.
* Recent smoking history or substance abuse (within six weeks).
* Heavy alcohol use (greater than 14 drinks per week for men or 7 drinks per week for women per NIAAA)
* Use of an investigational drug, device or product, or participation in a drug research study within a period of 30 days prior to receiving study treatment.
* Any patient who has received gene therapy in the past.
* Subjects who are currently on opioid medication(s).
* Body Mass Index (BMI) \> 40 kg/m2.

Contacts and Locations

Study Contact

Creative Medical Technology

CONTACT

(702) 588-1890

clinicaltrials@creativemedicaltechnology.com

Study Locations (Sites)

Spine and Wellness Centers of America

Aventura, Florida, 33180

United States

Collaborators and Investigators

Sponsor: Creative Medical Technology Holdings Inc

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-21

Study Completion Date2026-05-21

Study Record Updates

Study Start Date2024-05-21

Study Completion Date2026-05-21

Terms related to this study

Additional Relevant MeSH Terms

Chronic Low-back Pain
Degenerative Disc Disease